Regeneron Pharmaceuticals Inc Stock Research

Market Summary

USD749.75-10.55

Delayed

-1.39%

REGN Alerts

6 major insider sales recently.
Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)

REGN Stock Price

REGN RSI Chart

REGN Valuation

Market Cap

80.1B

Price/Earnings (Trailing)

18.47

Price/Sales (Trailing)

6.58

EV/EBITDA

14.65

Price/Free Cashflow

15.98

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

39.91%

Return on Equity

19.14%

Return on Assets

14.85%

Free Cashflow Yield

6.26%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

12.2B

Revenue Y/Y

-31.05%

Revenue Q/Q

16.29%

REGN Earnings

Earnings (TTM)

4.3B

Earnings Y/Y

-46.29%

Earnings Q/Q

-9.01%

Price Action

52 Week Range

538.01800.48

(Low)(High)

Last 7 days

2.0%

Last 30 days

-0.5%

Last 90 days

4.0%

Trailing 12 Months

14.2%

REGN Financial Health

Current Ratio

5.06

Debt/Equity

0.07

Debt/Cashflow

3.75

REGN Investor Care

Shares Dilution (1Y)

0.66%

Diluted EPS (TTM)

38.22

Peers (Alternatives to Regeneron Pharmaceuticals)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	304.8B	1.4B	-3.73%	61.04%	-152.12	215.28	20.37%	-37.45%
ABBV	275.0B	58.1B	0.21%	1.63%	23.24	4.74	3.30%	2.55%
REGN	80.1B	12.2B	-0.48%	14.17%	18.47	6.58	-24.26%	-46.28%
VRTX	77.3B	8.9B	-1.64%	19.14%	23.26	8.65	17.91%	41.84%
ALNY	23.5B	1.0B	-16.46%	21.47%	-20.78	22.66	22.88%	-32.64%
SRPT	13.2B	933.0M	21.02%	90.98%	-18.71	14.11	32.93%	-67.99%
UTHR	10.1B	1.9B	-15.04%	21.63%	13.93	5.23	14.88%	52.86%
MID-CAP
MDGL	4.5B	504.0K	-6.48%	165.34%	-15.07	2.5K	-66.53%	-22.12%
RARE	2.8B	363.3M	-7.03%	-36.05%	-3.99	7.77	3.39%	-55.81%
BPMC	2.7B	204.0M	2.71%	-22.88%	-4.84	13.22	13.30%	13.44%
MRTX	2.5B	12.4M	-10.70%	-44.17%	-3.35	199.44	-	-27.34%
SMALL-CAP
CPRX	1.6B	191.8M	-7.72%	90.19%	24.49	8.55	43.59%	60.82%
MGNX	429.6M	93.0M	-0.16%	-22.78%	-2.25	4.62	-19.83%	-30.37%
CRBP	24.0M	-	-31.83%	665.59%	-0.57	19.11	-77.61%	7.22%
CYTK	3.5M	94.6M	-15.04%	9.81%	-0.01	0.04	34.30%	-80.65%

Financials for Regeneron Pharmaceuticals

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-11.2%	12,173	13,710	14,227	16,508	16,072
S&GA Expenses	5.0%	2,116	2,015	1,931	1,869	1,825
R&D Expenses	9.3%	3,593	3,287	3,041	2,961	2,860
Costs and Expenses	-0.6%	7,434	7,478	7,372	7,416	7,125
EBITDA	-17.9%	5,260	6,409	6,696	9,483	9,669
EBITDA Margin	-7.6%	0.43*	0.47*	0.45*	0.57*	0.60*
Earnings Before Taxes	-19.5%	4,859	6,038	6,344	9,134	9,326
EBT Margin	-9.4%	0.40*	0.44*	0.42*	0.55*	0.58*
Interest Expenses	5.9%	59.00	56.00	55.00	56.00	57.00
Net Income	-19.2%	4,338	5,370	5,687	7,934	8,075
Net Income Margin	-9.0%	0.36*	0.39*	0.38*	0.48*	0.50*
Free Cahsflow	-11.5%	5,015	5,668	8,452	8,515	7,081

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	5.6%	29,215	27,678	27,206	26,349	25,435
Current Assets	3.0%	15,884	15,429	15,530	14,306	14,015
Cash Equivalents	-11.0%	3,106	3,491	3,395	3,346	2,886
Inventory	-0.4%	2,402	2,412	2,219	1,992	1,951
Net PPE	1.8%	3,704	3,638	3,556	3,482	-
Liabilities	5.0%	6,551	6,239	6,518	6,434	6,666
Current Liabilities	9.1%	3,141	2,879	3,034	3,008	3,933
Long Term Debt	-10.3%	1,513	1,686	1,887	-	-
LT Debt, Non Current	0.0%	1,981	1,981	1,981	1,980	1,980
Shareholder's Equity	5.7%	22,664	21,439	20,688	19,915	18,769
Retained Earnings	5.4%	23,307	22,110	20,794	19,942	18,968
Additional Paid-In Capital	4.5%	9,949	9,518	9,120	8,754	8,088
Shares Outstanding	-0.9%	107	108	107	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-11.5%	5,015	5,668	8,452	8,515	7,081
Share Based Compensation	6.4%	725	681	652	638	602
Cashflow From Investing	3.9%	-3,784	-3,939	-6,570	-6,031	-5,384
Cashflow From Financing	39.5%	-1,009	-1,668	-557	-574	-1,005
Buy Backs	-17.5%	2,083	2,526	1,803	1,698	1,645

Risks for REGN

What is the probability of a big loss on REGN?

71.2%

Probability that Regeneron Pharmaceuticals stock will be more than 20% underwater in next one year

35.8%

Probability that Regeneron Pharmaceuticals stock will be more than 30% underwater in next one year.

6.5%

Probability that Regeneron Pharmaceuticals stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for REGN

Cumulative Returns on REGN

16.0%

10-Year Cumulative Returns

10.9%

7-Year Cumulative Returns

17.2%

5-Year Cumulative Returns

17.8%

3-Year Cumulative Returns

What are the long-term rolling returns for REGN?

FIve years rolling returns for Regeneron Pharmaceuticals.

Annualized Returns

Which funds bought or sold REGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	reduced	-23.00	-224,477	937,523	0.03%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-1.83	1,789,050	65,144,100	0.07%
2023-03-10	BAILLIE GIFFORD & CO	unchanged	-	1,910	33,910	-%
2023-03-10	MATHER GROUP, LLC.	added	3.41	19,139	241,139	-%
2023-03-08	SHEETS SMITH WEALTH MANAGEMENT	unchanged	-	14,671	324,671	0.05%
2023-03-06	OLD MISSION CAPITAL LLC	sold off	-100	-338,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-6.7	-1,274,000	54,461,000	0.27%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	new	-	202,017	202,017	0.01%
2023-03-03	TIAA, FSB	added	50.62	735,350	2,009,350	0.01%
2023-03-02	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	new	-	9,088,600	9,088,600	0.11%

Latest Funds Activity

Are funds buying REGN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own REGN

No. of Funds

Regeneron Pharmaceuticals News

Schedule 13G FIlings of Regeneron Pharmaceuticals

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	capital world investors	5.9%	6,315,819	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.15%	8,722,448	SC 13G/A
Feb 03, 2023	blackrock inc.	8.6%	9,166,817	SC 13G/A
Jan 11, 2023	jpmorgan chase & co	5.6%	6,101,044	SC 13G
Feb 11, 2022	capital world investors	5.1%	5,391,870	SC 13G/A
Feb 10, 2022	vanguard group inc	7.72%	8,158,515	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 01, 2022	blackrock inc.	9.1%	9,610,871	SC 13G/A
Feb 16, 2021	capital world investors	6.7%	7,017,122	SC 13G/A

REGN Fair Value

Regeneron Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Regeneron Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	1024.59 36.66%	1399.74 86.69%	1972.26 163.06%	2986.22 298.30%	3604.06 380.70%
Very High Inflation	- -	- -	- -	- -	- -

Historical Regeneron Pharmaceuticals Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Regeneron Pharmaceuticals

View All Filings

Date Filed	Form Type	Document
Mar 14, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Feb 24, 2023	4	Insider Trading
Feb 14, 2023	4	Insider Trading
Feb 13, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 08, 2023	4	Insider Trading
Feb 08, 2023	4	Insider Trading

Latest Insider Trading transactions for REGN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-10	LAROSA JOSEPH J	gifted	-	-	-1,006	evp general counsel and secret
2023-03-01	RYAN ARTHUR F	sold	-76,249	762	-100	-
2023-03-01	McCourt Marion	acquired	409,706	372	1,100	evp commercial
2023-03-01	McCourt Marion	sold	-835,879	759	-1,100	evp commercial
2023-02-22	VAGELOS P ROY	sold (taxes)	-21,758,400	750	-29,005	-
2023-02-22	VAGELOS P ROY	acquired	11,493,300	270	42,500	-
2023-02-12	McCourt Marion	sold (taxes)	-959,271	751	-1,276	evp commercial
2023-02-07	McCourt Marion	sold	-769,040	769	-1,000	evp commercial
2023-02-07	McCourt Marion	acquired	372,460	372	1,000	evp commercial
2023-02-06	GOLDSTEIN JOSEPH L	acquired	1,743,920	482	3,613	-

About Regeneron Pharmaceuticals

Leonard S. Schleifer

www.regeneron.com

10400

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Income Statement

2022-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Revenues	$ 2,936.2	$ 3,452.8	$ 8,758.5	$ 11,120.0
Expenses:
Research and development	911.3	665.4	2,549.4	2,122.5
Acquired in-process research and development	0.0	0.0	225.1	0.0
Selling, general, and administrative	529.1	445.0	1,455.4	1,265.3
Other operating (income) expense, net	(45.7)	42.0	(83.3)	(29.8)
Costs and expenses, total	1,712.5	1,605.6	5,166.4	4,812.9
Income from operations	1,223.7	1,847.2	3,592.1	6,307.1
Other income (expense):
Other income (expense), net	301.4	(16.4)	(16.0)	558.5
Interest expense	(15.3)	(14.2)	(42.0)	(43.2)
Total other income (expense)	286.1	(30.6)	(58.0)	515.3
Income before income taxes	1,509.8	1,816.6	3,534.1	6,822.4
Income tax expense	194.1	184.4	392.8	976.1
Net income	$ 1,315.7	$ 1,632.2	$ 3,141.3	$ 5,846.3
Net income per share - basic (in dollars per share)	$ 12.31	$ 15.37	$ 29.30	$ 55.42
Net income per share - diluted (in dollars per share)	$ 11.66	$ 14.33	$ 27.73	$ 52.29
Weighted average shares outstanding - basic (in shares)	106.9	106.2	107.2	105.5
Weighted average shares outstanding - diluted (in shares)	112.8	113.9	113.3	111.8
Statements of Comprehensive Income
Net income	$ 1,315.7	$ 1,632.2	$ 3,141.3	$ 5,846.3
Other comprehensive income (loss), net of tax:
Unrealized loss on debt securities	(51.3)	(6.4)	(249.9)	(20.5)
Unrealized gain on cash flow hedges	0.0	0.2	1.0	0.7
Comprehensive income	1,264.4	1,626.0	2,892.4	5,826.5
Net product sales
Revenues:
Revenues	1,801.4	2,279.9	5,194.4	8,142.0
Expenses:
Cost of goods, collaboration and contract manufacturing	141.3	238.8	497.8	961.4
Collaboration revenue
Revenues:
Revenues	1,050.6	1,073.9	3,326.7	2,783.0
Other revenue
Revenues:
Revenues	84.2	99.0	237.4	195.0
Cost of collaboration and contract manufacturing
Expenses:
Cost of goods, collaboration and contract manufacturing	$ 176.5	$ 214.4	$ 522.0	$ 493.5

REGN Balance Sheet

2022-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 3,491.3	$ 2,885.6
Marketable securities	3,530.4	2,809.1
Accounts receivable, net	5,548.3	6,036.5
Inventories	2,412.2	1,951.3
Prepaid expenses and other current assets	446.4	332.4
Total current assets	15,428.6	14,014.9
Marketable securities	5,968.6	6,838.0
Property, plant, and equipment, net	3,704.2	3,482.2
Intangible assets, net	804.1	6.7
Deferred tax assets	1,452.1	876.9
Other noncurrent assets	320.2	216.1
Total assets	27,677.8	25,434.8
Current liabilities:
Accounts payable	535.6	564.0
Accrued expenses and other current liabilities	1,796.4	2,206.8
Finance lease liabilities	0.0	719.7
Deferred revenue	547.2	442.0
Total current liabilities	2,879.2	3,932.5
Long-term debt	1,981.1	1,980.0
Finance lease liabilities	720.0	0.0
Deferred revenue	60.1	73.3
Other noncurrent liabilities	598.6	680.2
Total liabilities	6,239.0	6,666.0
Stockholders' equity:
Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none	0.0	0.0
Additional paid-in capital	9,518.2	8,087.5
Retained earnings	22,109.6	18,968.3
Accumulated other comprehensive loss	(275.1)	(26.2)
Treasury Stock, at cost; 22.0 shares in 2022 and 19.4 shares in 2021	(9,914.0)	(8,260.9)
Total stockholders' equity	21,438.8	18,768.8
Total liabilities and stockholders' equity	27,677.8	25,434.8
Class A Stock
Stockholders' equity:
Common stock	0.0	0.0
Common Stock
Stockholders' equity:
Common stock	$ 0.1	$ 0.1